EKTA.Y Stock Overview
A medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Elekta AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 5.79 |
| 52 Week High | SEK 8.62 |
| 52 Week Low | SEK 5.52 |
| Beta | 1.12 |
| 11 Month Change | -9.57% |
| 3 Month Change | -14.14% |
| 1 Year Change | -30.87% |
| 33 Year Change | -51.76% |
| 5 Year Change | -53.31% |
| Change since IPO | 136.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| EKTA.Y | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.2% | 0.9% | 2.2% |
| 1Y | -30.9% | 21.9% | 32.6% |
Return vs Industry: EKTA.Y underperformed the US Medical Equipment industry which returned 20.8% over the past year.
Return vs Market: EKTA.Y underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| EKTA.Y volatility | |
|---|---|
| EKTA.Y Average Weekly Movement | 4.5% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EKTA.Y has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EKTA.Y's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 4,566 | Gustaf Salford | elekta.com |
Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software.
Elekta AB (publ) Fundamentals Summary
| EKTA.Y fundamental statistics | |
|---|---|
| Market cap | US$2.23b |
| Earnings (TTM) | US$103.15m |
| Revenue (TTM) | US$1.65b |
21.7x
P/E Ratio1.4x
P/S RatioIs EKTA.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EKTA.Y income statement (TTM) | |
|---|---|
| Revenue | SEK 18.12b |
| Cost of Revenue | SEK 11.49b |
| Gross Profit | SEK 6.63b |
| Other Expenses | SEK 5.50b |
| Earnings | SEK 1.13b |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
Nov 27, 2024
| Earnings per share (EPS) | 2.97 |
| Gross Margin | 36.60% |
| Net Profit Margin | 6.26% |
| Debt/Equity Ratio | 60.6% |
How did EKTA.Y perform over the long term?
See historical performance and comparison